OS Therapies Incorporated

OS Therapies Incorporated is a clinical-stage biopharmaceutical company dedicated to identifying, advancing, and commercializing therapeutic solutions for osteosarcoma and other solid tumors within the United States. Its pipeline highlights OST-HER2, a readily available immunotherapy developed for osteosarcoma patients, alongside OST-tunable drug conjugate (OST-tADC). This innovative antibody-drug conjugate technology leverages a modular 'plug-and-play' platform equipped with customizable, pH-sensitive silicone linkers. Established in 2018, OS Therapies Incorporated is headquartered in Rockville, Maryland.